Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC
Clinical trial NCT07663747 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07663747
- Sponsor
- The Netherlands Cancer Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-01
- Primary completion
- 2031-04-01
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.